Induced Pluripotent Stem Cells
GMP iPSC reprogramming, gene editing and differentiation
Leading Industry Experts
OmniaBio has generated and characterized over 200 induced pluripotent stem cell (iPSC) lines. This deep expertise ensures we can meet the unique requirements of each client. Our team of iPSC industry leaders take a personalized approach to each project and can help you at every step.
iPSC CDMO Offerings
- Good Manufacturing Practices (GMP)-compliant reprogramming platforms to produce therapeutic-grade iPSC lines
- Expertise using a variety of different nucleases and delivery methods, including CRISPR-Cas9, to generate gene-edited iPSC lines with knock-in, knock-out, and single nucleotide polymorphism (SNP) modifications
- An optimized screening approach for fast and accurate identification of single-cell clones of interest
- Process scale-up for the generation of a variety of differentiated cell types
- An in-house analytics platform to enable cell line characterization
Services for Your Project Phase
Process
Development
Experts in optimization to ensure reliable scale-up to produce cell and gene therapies.
GMP
Manufacturing
Our state-of-the-art facility is equipped with the tools and flexibility to manufacture your product at commercial scale.
Analytical
Development
Providing a robust suite of analytical capabilities that are integrated through your product’s lifecycle to support the development process.
Regulatory
Support
With in-depth knowledge, we can guide you through the regulatory landscape to approval.
Our Expertise on Demand
Related Thought Leadership & Resources
CDMO collaboration propels cell replacement therapy targeting Duchenne muscular dystrophy forward, with consequences for the role of AI in cell therapy. September 9, 2024 (BOSTON, MA and HAMILTON, Ontario) – Somite Therapeutics, a tech-bio company harnessing big...
CCRM and OmniaBio spin-off provides high-quality iPSC lines that expedite time to GMP by 12 months and reduce cell line development costs by up to 60%. July 30, 2024 (Toronto, Ontario) – LineaBio, a cell line...
June 12, 2024 (Hamilton, Ontario) – OmniaBio Inc. is pleased to announce the appointment of Kenneth (Ken) L. Harris as its Chief Strategy Officer and Head of Artificial Intelligence (AI), strengthening its mandate of bringing...